In the late 2000s, a strange kind of footwear appeared in American malls, gyms and office corridors: a chunky sneaker with a curved, rocker-shaped sole that made the wearer wobble slightly with every step. The Skechers Shape-Ups promised something almost magical, that simply walking in them would tone your legs, firm your backside, burn extra calories and even help you lose weight. For a few years, millions of people believed it. Then the science, the regulators and the courts caught up, and one of the most successful fitness-footwear fads in history collapsed almost as fast as it had risen.
The Origins of the Toning Shoe
The concept did not originate with Skechers. Swiss engineer Karl Müller developed the Masai Barefoot Technology (MBT) shoe in the 1990s, inspired by the way he observed the Masai people walking on soft ground in Kenya. His curved-sole design was marketed as a way to reduce joint stress and engage stabilizing muscles. MBT shoes were expensive and aimed at a niche audience, but they established the idea that an unstable sole could turn ordinary walking into exercise.
Skechers, the California-based company known largely for casual and youth-oriented footwear, saw the opportunity to bring the idea to the mass market. Introduced in 2008, Shape-Ups were priced affordably and sold at nearly every major retailer. The marketing leaned hard on the body-transformation promise: wear these shoes and you could get a workout without working out. Celebrity endorsements from figures like Kim Kardashian and Brooke Burke reinforced the message, and the ads were everywhere.
A Genuine Phenomenon
The financial results were extraordinary. Skechers’ revenue surged, and by 2010 the company had passed $2 billion in annual sales, with toning shoes accounting for a huge share of that growth. Shape-Ups were widely reported to have generated well over a billion dollars in sales during their peak years. Competitors rushed to copy the formula. Reebok launched its EasyTone line, New Balance introduced its Rock & Tone shoes, and Nike entered the market with the Shox Tone Up. For a brief period, toning footwear was one of the hottest categories in the entire athletic industry.
The appeal was easy to understand. Americans wanted fitness results with minimal effort, and a pair of shoes offered a painless shortcut. Consumers could feel the instability underfoot and sense their muscles working, which gave the sensation of effectiveness even where the evidence was lacking.
The Science Pushes Back
The first serious cracks appeared when independent researchers began testing the claims. In 2010, a study conducted at the University of Wisconsin-La Crosse for the American Council on Exercise compared toning shoes against ordinary sneakers. The researchers found no meaningful difference in muscle activation, calorie burn or exercise intensity. The shoes did not tone the muscles any better than regular footwear did. Other studies reached similar conclusions, and the broader scientific community grew skeptical that wobbling slightly while walking could reshape the body.
There were also safety concerns. Podiatrists and orthopedic specialists reported patients with sprained ankles, foot pain, and other injuries they attributed to the unstable soles. A wave of personal injury lawsuits followed, with plaintiffs claiming that the shoes had caused falls and other harm. The idea that these shoes were not merely ineffective but potentially hazardous damaged their reputation further.
Regulators and Lawsuits
The decisive blow came from the legal system. In 2010, consumer class action lawsuits began piling up, alleging that Skechers had made deceptive claims about the health and fitness benefits of its toning shoes. State attorneys general and the Federal Trade Commission launched their own investigations.
In May 2012, Skechers agreed to pay $40 million to settle FTC charges that it had deceived consumers with unfounded claims. The FTC alleged that the company had made unsupported assertions that Shape-Ups would help people lose weight, tone their muscles and improve overall fitness. The $40 million went toward consumer refunds. Combined with a separate class action settlement involving dozens of states and private plaintiffs, the total cost to the company was reported to be around $50 million. Skechers did not admit wrongdoing, but it agreed to stop making unsubstantiated health claims in its advertising. Reebok had faced a similar fate the year before, settling with the FTC for $25 million over its EasyTone claims.
The Collapse in Sales
The sales decline began even before the settlements. As negative press, scientific studies and lawsuits accumulated, consumer enthusiasm cooled quickly. Fads thrive on momentum, and once the claims were publicly questioned, the momentum reversed. Skechers’ toning shoe sales dropped sharply in 2011, and the company’s stock price fell substantially from its earlier highs. Retailers that had dedicated large amounts of floor space to toning footwear found themselves with unsold inventory. By the middle of the decade, the entire category had essentially vanished from mainstream retail.
Skechers’ Recovery
What makes the story remarkable is that Skechers survived, and thrived. Rather than being crippled by the scandal, the company pivoted. It had already begun investing in performance running shoes through its GOrun line, and it expanded its comfort-oriented walking lines such as GOwalk. It also built a very successful business around memory-foam cushioning and affordable, comfortable casual shoes, a segment that appealed to the same broad customer base that had once bought Shape-Ups. In later years, innovations like the Hands Free Slip-ins further drove growth. Skechers went on to become one of the largest footwear companies in the world, with annual revenues well above those of the Shape-Ups era. The toning shoe fiasco turned out to be a costly detour rather than a fatal blow.
Lessons from the Fad
The story of Shape-Ups offers several lessons. First, extraordinary marketing claims require extraordinary evidence. Skechers promised physiological benefits it could not substantiate, and regulators made it pay. Second, consumer demand for effortless fitness is persistent, and companies will always be tempted to exploit it. Similar patterns have appeared with electric muscle stimulators, detox teas and other shortcut products. Third, the episode showed how quickly a retail boom can unravel once scientific scrutiny and legal pressure converge.
Interestingly, the rocker-bottom sole itself did not disappear. Modern running shoe brands like Hoka and others use curved, cushioned soles to promote smooth transitions and reduce impact. The difference is that today’s shoes are marketed on comfort and performance rather than on promises of sculpted glutes.
The Skechers Shape-Ups did not vanish by accident. They were undone by a gap between marketing and reality: studies showing no added fitness benefit, reports of injuries, and a multimillion-dollar FTC settlement over deceptive advertising. Yet the company that made them adapted and ultimately flourished. Today, Shape-Ups stand as a cautionary tale of the late-2000s fitness fad era, a reminder that there is rarely a shortcut to toned muscles, and that no shoe, however cleverly designed, can do the work of actual exercise.